STOCK TITAN
  1. Home
  2. News
  3. NAUT

Nautilus Biotechnology to Participate in Upcoming August Investor Conferences

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Nautilus Biotechnology, Inc. (NASDAQ: NAUT) announces participation in investor conferences and panel discussions on proteomics and genomics.
Positive
  • None.
Negative
  • None.

SEATTLE, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the following investor conferences:

  • Canaccord 43rd Annual Growth Conference in Boston, MA
    Management will participate in “The Next Generation of Proteomics from the Research and Clinical Perspectives” Panel on Thursday, August 10th at 10:00 a.m. Eastern Time
  • UBS MedTech, Tools and Genomics Summit 2023 in Dana Point, CA
    Management will host 1x1 investor meetings on Tuesday, August 15th

About Nautilus Biotechnology, Inc.
With its corporate headquarters in Seattle, Washington and its research and development headquarters in San Carlos, California, Nautilus is a development stage life sciences company working to create a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit www.nautilus.bio.

Media Contact
press@nautilus.bio

Investor Contact
investorrelations@nautilus.bio

 


Nautilus Biotechnology is participating in Canaccord 43rd Annual Growth Conference in Boston and UBS MedTech, Tools and Genomics Summit 2023 in Dana Point.

Nautilus Biotechnology's management will participate in 'The Next Generation of Proteomics from the Research and Clinical Perspectives' Panel at the Canaccord conference.

The panel discussion is scheduled for Thursday, August 10th at 10:00 a.m. Eastern Time.

Nautilus Biotechnology's management will host 1x1 investor meetings on Tuesday, August 15th at the UBS Summit.
Stock NAUT logo
Nautilus Biotechnology Inc

NASDAQ:NAUT

NAUT Rankings

#3377 Ranked by Market Cap
#2135 Ranked by Stock Gains
N/A Ranked by Dividends

NAUT Latest News

Apr 11, 2024
Nautilus Biotechnology to Announce First Quarter 2024 Financial Results on April 30, 2024
Feb 28, 2024
Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2023 Financial Results
Feb 22, 2024
Nautilus Biotechnology to Participate in the TD Cowen 44ᵗʰ Annual Healthcare Conference
Feb 7, 2024
Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
Nov 30, 2023
Nautilus Biotechnology Co-founder and Chief Scientist Parag Mallick, Ph.D., Honored with US HUPO Computational Proteomics Award

NAUT Stock Data

Analytical Laboratory Instrument Manufacturing
Manufacturing

About NAUT

born from the founders’ recognition that their diverse but complementary skills and experiences would enable them to successfully address challenges that others had not, the company set about solving a vexing problem: how to bring true proteomics to the world in a way that accelerates therapeutic development, dramatically improves medical diagnostics, and makes personalized and predictive medicine a reality. the extraordinary team at nautilus represents a wide spectrum of disciplines and expertise, including: protein chemists, chip designers, molecular biologists, data scientists, material scientists, biophysicists, optical engineers, microfluidics engineers, bioinformaticists, software engineers, and more. nautilus is positioned to revolutionize proteomics, transform the way drugs are developed, and significantly improve the way human health is managed.